An interventional study of Herpes zoszter (acute)with inter vention in Herper Zoster, sponsored by Keimyung University Dongsan Medical Center. Completed at 1 site in South Korea. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-25.
Sponsored by Keimyung University Dongsan Medical Center · Not applicable, Interventional, and Treatment
Investigators performed this study to investigate the expression levels inflammatory cytokine and neurotransmitters (calcitonin gene-related peptide (CGRP), substance P (SP), vasoactive intestinal peptide (VIP), and β-endorphin) in peripheral blood of participants with herpes zoster.
Sudden and electrick shooting sensation of face is an important clinical feature of herpes zoster. The severe and excruciating nature of pain intensity associated with herpes zoster can impair the physical and psychosocial well-being of the patient, however, pathophysiologic mechanism of herpes zoster still remains unclear.
Recentrly, there have been a few studies suggesting biomarker levels in the blood and CSF level, however, further study is required to elucidate the action mechanism.
Up to 90% of patients can achieve pain reduction using medical therapy alone. However, 10% -15% of herpes zoster cases demonstrate a minimal response to medication with various side effects. Radiofrequency thermocoagulation (RFT) of the trigeminal ganglion is an alternative treatment option for patients who are poor candidates for microvascular decompression or show serious side effects to medication. Recent study revealed that RFT of the trigeminal ganglion resulted in Barrow Neurological Institute (BNI) pain scale I or II in 71.7% of patients, with a median time to recurrence of 36 months.
Although patients experience significant pain relief after RFT, it is uncertain whether inflammatory cytokine and neurocytokine (CGRP, substance P, VIP) are reduced.
360 studies on the registry are indexed under Herpes Zoster; 60 are open to participants now.
This study's enrollment of 30 is below the median of 250 across 299 interventional studies indexed under Herpes Zoster.
Browse Herpes Zoster studies →Keimyung University Dongsan Medical Center is the lead sponsor of 81 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with herpes zoster receiving 2 times of nerve block
Procedure: Herpes zoszter (acute)with inter vention
Patients with herpes zoster receiving 2 times of nerve block
Procedure: Herpes zoszter (acute)with inter vention
nerve block
serum level of inflammatory cytokine changes during 3 time period
inflammatory cytokine including Tumor necrosis factor-alpha, Interleukin-6 changes during 3 time period Higher score means worse outcome
Time frame: Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
serum level of neurotransmitter changes during 3 time period
neurotransmitter including Calcitonene gene related peptide, substance P, vasoactive intestitinal polypeptide changes during 3 time period Higher score means worse outcome
Time frame: Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
Changes of numerical rating scale changes during 3 time period
numerical rating scale changes during 3 time period
Time frame: Baseline, 1 week after tigeminal nerve block, 2 weeks after radiofrequency thermocoagulation
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Keimyung University Dongsan Medical Center